PT3394083T - Derivados de n-[5-[(3,4-dimetoxifenil)metil]-1,3,4-tiadiazol-2-il]-2-metoxi-benzenoacetamida e compostos relacionados como ativadores de cftr para tratar a obstipação ou colestase - Google Patents

Derivados de n-[5-[(3,4-dimetoxifenil)metil]-1,3,4-tiadiazol-2-il]-2-metoxi-benzenoacetamida e compostos relacionados como ativadores de cftr para tratar a obstipação ou colestase

Info

Publication number
PT3394083T
PT3394083T PT168801561T PT16880156T PT3394083T PT 3394083 T PT3394083 T PT 3394083T PT 168801561 T PT168801561 T PT 168801561T PT 16880156 T PT16880156 T PT 16880156T PT 3394083 T PT3394083 T PT 3394083T
Authority
PT
Portugal
Prior art keywords
methods
cftr
regulators
cftr regulators
Prior art date
Application number
PT168801561T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of PT3394083T publication Critical patent/PT3394083T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Prostheses (AREA)
PT168801561T 2015-12-24 2016-12-23 Derivados de n-[5-[(3,4-dimetoxifenil)metil]-1,3,4-tiadiazol-2-il]-2-metoxi-benzenoacetamida e compostos relacionados como ativadores de cftr para tratar a obstipação ou colestase PT3394083T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562387591P 2015-12-24 2015-12-24

Publications (1)

Publication Number Publication Date
PT3394083T true PT3394083T (pt) 2021-12-07

Family

ID=59091233

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168801561T PT3394083T (pt) 2015-12-24 2016-12-23 Derivados de n-[5-[(3,4-dimetoxifenil)metil]-1,3,4-tiadiazol-2-il]-2-metoxi-benzenoacetamida e compostos relacionados como ativadores de cftr para tratar a obstipação ou colestase

Country Status (15)

Country Link
US (2) US20190031630A1 (https=)
EP (1) EP3394083B9 (https=)
JP (1) JP6894902B2 (https=)
KR (1) KR102723194B1 (https=)
CN (1) CN108699107B (https=)
AU (2) AU2016377782B2 (https=)
CL (1) CL2018001714A1 (https=)
CO (1) CO2018007239A2 (https=)
ES (1) ES2901002T3 (https=)
IL (2) IL299924B2 (https=)
PL (1) PL3394083T3 (https=)
PT (1) PT3394083T (https=)
RU (1) RU2742934C2 (https=)
WO (1) WO2017112947A1 (https=)
ZA (1) ZA201804228B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383072B (es) 2015-12-24 2025-03-13 Univ California Reguladores del cftr y métodos para su uso
IT201700085714A1 (it) * 2017-07-26 2019-01-26 Luigi Maiuri Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine.
JP2020531511A (ja) * 2017-08-24 2020-11-05 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 眼球用医薬組成物
FR3096890B1 (fr) * 2019-06-07 2021-05-14 H4 Orphan Pharma Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique.
US20220071549A1 (en) * 2020-09-08 2022-03-10 The Regents Of The University Of California Apparatus, systems and methods of use for ocular surface potential difference measurement
AU2021363703A1 (en) 2020-10-23 2023-06-22 S2Cbio Inc. Cftr modulator compounds, compositions, and uses thereof
CN113527225B (zh) * 2021-07-15 2022-11-18 南昌大学 一种丙烯酰噻二唑衍生物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010042298A (ko) 1998-03-31 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 인자 Xa 및 트롬빈과 같은 세린 프로테아제억제제로서의 퀴녹살리논
AU2003277162C1 (en) * 2002-09-30 2009-12-24 The Regents Of The University Of California Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
MXPA06008606A (es) * 2004-01-30 2007-04-13 Vertex Pharma Moduladores de transportadores con casete de union a atp.
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US20090105240A1 (en) * 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
EP2247580B1 (en) 2008-03-05 2015-07-08 Merck Patent GmbH Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
US8314239B2 (en) 2008-10-23 2012-11-20 Vertex Pharmaceutical Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2010073011A2 (en) * 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
WO2012092471A2 (en) * 2010-12-29 2012-07-05 Development Center For Biotechnology Novel tubulin inhibitors and methods of using the same
CA2942386A1 (en) * 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA2952862A1 (en) * 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity

Also Published As

Publication number Publication date
US20200140402A1 (en) 2020-05-07
EP3394083B1 (en) 2021-09-01
AU2016377782B2 (en) 2021-07-29
CN108699107B (zh) 2022-05-10
IL299924A (en) 2023-03-01
IL299924B2 (en) 2025-01-01
AU2021257948A1 (en) 2021-11-25
EP3394083A1 (en) 2018-10-31
US20190031630A1 (en) 2019-01-31
ZA201804228B (en) 2020-09-30
KR102723194B1 (ko) 2024-10-28
CL2018001714A1 (es) 2018-10-26
US11192869B2 (en) 2021-12-07
ES2901002T3 (es) 2022-03-21
RU2018126959A3 (https=) 2020-08-20
NZ743720A (en) 2024-08-30
CN108699107A (zh) 2018-10-23
AU2016377782A1 (en) 2018-07-12
CO2018007239A2 (es) 2018-07-19
IL299924B1 (en) 2024-09-01
BR112018012927A2 (en) 2018-12-11
WO2017112947A1 (en) 2017-06-29
IL260210B2 (en) 2023-06-01
JP6894902B2 (ja) 2021-06-30
IL260210A (en) 2018-07-31
RU2742934C2 (ru) 2021-02-11
EP3394083B9 (en) 2022-04-27
PL3394083T3 (pl) 2022-01-17
AU2021257948B2 (en) 2023-11-30
KR20180101415A (ko) 2018-09-12
ES2901002T9 (es) 2022-06-20
JP2018538354A (ja) 2018-12-27
CA3009531A1 (en) 2017-06-29
EP3394083A4 (en) 2019-09-04
RU2018126959A (ru) 2020-01-24

Similar Documents

Publication Publication Date Title
HUS2400028I1 (hu) PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
IL286316A (en) New micro-dystrophins and related method of use
IL282572B (en) Tetrahydropyranylamino-pyrrolopyrimidinone and methods of using it
IL289976A (en) Oxysterols and methods of using them
IL256179A (en) lag-3 binding molecules and methods of using them
IL250415B (en) Antibodies against pd-l and methods of using them
IL256710A (en) Oxysterols and methods of using them
HUE068842T2 (hu) Vegyületek és alkalmazási eljárásaik
SG11201803213XA (en) Glycan-interacting compounds and methods of use
IL282482A (en) Variants of protoxin-II and methods of use
ZA201804228B (en) Cftr regulators and methods of use thereof
IL282508A (en) Variants of protoxin-II and methods of use
ZA201804230B (en) Cftr regulators and methods of use thereof
ZA201804229B (en) Cftr regulators and methods of use thereof
SG10201912615PA (en) Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof